By Jeff Overley ( August 20, 2015, 8:56 PM EDT) -- Otsuka Pharmaceutical Co. Ltd. and Alkermes Inc. are in a tough war of words as the U.S. Food and Drug Administration weighs approval of an Alkermes product that would directly compete with Otsuka's long-acting schizophrenia drug Abilify Maintena, newly released correspondence shows....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.